Compare AbCellera Biologics Inc (ABCL) vs Teradyne, Inc. (TER) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Teradyne, Inc. — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Teradyne, Inc. trades at $348.1 (market cap $53.71B). The key difference: Teradyne, Inc. is far larger — about 22.9× AbCellera Biologics Inc's market cap, and Teradyne, Inc. pays a 0.15% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | TER | |
|---|---|---|
Market Cap | $2.35B | $53.71B |
Sector | Health | Technology |
52-Week High | $8.12 | $483.84 |
52-Week Low | $2.78 | $90.15 |
Enterprise Value | $1.99B | $53.55B |
Dividend Yield | — | 0.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Teradyne (TER) trades at $343.11, down 7.04% amid a semiconductor sector sell-off, yet maintains strong fundamentals with 22.55% net margins and consistent earnings beats. The stock shows bearish technical signals but benefits from robust AI-driven demand, with 64.5% analyst buy ratings and a $453.60 consensus target suggesting 32% upside. Recent dividend declaration and strong cash flow generation support long-term stability despite near-term volatility.
Outlook remains positive given Teradyne's leadership in semiconductor testing and robotics, with AI infrastructure spending driving growth. Risks include sector cyclicality and premium valuations (P/E 70.4), but earnings momentum and institutional support provide cushion. The stock presents a compelling opportunity for investors seeking AI infrastructure exposure with proven execution capabilities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
